Halozyme Therapeutics Inc

Financials

Fluxo de caixa operacional 178.47 M154.22 M99.71 M178.6 M219.03 M 651.56 M Fluxo de caixa de investimento 29.48 M-90.42 M84.79 M201.61 M-741.79 M -545.81 M Fluxo de caixa de financiamento -246.41 M-3.32 M-298.97 M-22.4 M239.51 M -85.17 M Fluxo de caixa livre 175.41 M153.27 M98.15 M175.57 M217.6 M 644.59 M

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

HALO

Financials

Halozyme Therapeutics Inc

Notícias

Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?

TD Cowen reitera recomendação de compra para ações da Halozyme com base no crescimento de royalties

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

CEO da Halozyme Therapeutics vende US$ 634.981 em ações

Halozyme licencia tecnologia Hypercon para a Vertex por US$ 15 milhões

Leerink reitera classificação das ações da Halozyme após acordo com a Vertex

Leaderboard Trimmed, But Cloudflare, Caterpillar Among 5 Stocks To Watch

JNJ: Success In Multiple Myeloma Underpins $25B In Growth By 2030 (NYSE:JNJ)

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme nomeia David Ramsay como CFO interino

Halozyme names David Ramsay as interim CFO

Halozyme apresenta planos de crescimento estratégico e inovações